Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 0.82 |
| ▸ | TDO2 | P48775 | 15/20 | 0.82 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | UBE2M | P61081 | 1/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138014 | 0.90 | IDO1 (1.00) | IDO1TDO2CYP2C8CYP2C9 | |
| SCHEMBL21138420 | 0.86 | IDO1 (0.89) | IDO1TDO2CYP2C8CYP2C9 | |
| SCHEMBL21138832 | 0.86 | IDO1 (0.79) | IDO1TDO2CYP2C8CYP2C9 | |
| SCHEMBL21138049 | 0.86 | IDO1 (0.79) | IDO1TDO2CYP2C8CYP2C9 | |
| SCHEMBL21138831 | 0.84 | IDO1 (0.77) | IDO1TDO2CYP2C8CYP2C9 | |
| SCHEMBL21138834 | 0.84 | IDO1 (0.79) | IDO1TDO2CYP2C8CYP2C9 | |
| SCHEMBL21138423 | 0.83 | IDO1 (0.82) | IDO1TDO2CYP2C8CYP2C9 | |
| SCHEMBL21137992 | 0.83 | IDO1 (1.00) | IDO1TDO2CYP2C8CYP2C9 | |
| SCHEMBL21138429 | 0.82 | IDO1 (0.79) | IDO1TDO2CYP2C8CYP2C9 | |
| SCHEMBL21138833 | 0.82 | IDO1 (0.81) | IDO1TDO2CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
| WO-2019115586-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | IDO1 1/4885TDO2 7/4885CYP2C8 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.